LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Sensitive Epigenetic-Based PCR Test Could Detect Difficult-To-Diagnose Breast Tumor

By LabMedica International staff writers
Posted on 05 Feb 2024
Image: Scientists have discovered biomarkers for rare breast tumors (Photo courtesy of Garvan Institute)
Image: Scientists have discovered biomarkers for rare breast tumors (Photo courtesy of Garvan Institute)

Phyllodes tumors, which make up less than 1% of breast tumors, present a diagnostic challenge due to their microscopic resemblance to other breast tumor types. While the majority of phyllodes tumors are benign, about 10% are malignant. Getting an accurate diagnosis is key to ensuring the right treatment is given, as a misdiagnosis can lead to inappropriate or delayed care. Typically, tumor diagnosis is based on the pathological examination of cellular patterns. Now, scientists have found the epigenetic ‘signature’ of phyllodes tumors, paving the way for the development of a sensitive epigenetic-based PCR test to detect this hard-to-diagnose breast tumor that could be routinely used in pathology laboratories.

Scientists at the Garvan Institute of Medical Research (NSW, Australia) have identified new DNA markers based on epigenetics that could provide additional diagnostic information for phyllodes tumors. Epigenetic alterations involve changes in gene activity levels without modifying the DNA sequence itself and can be influenced by environmental factors. One common epigenetic process is DNA methylation, where methyl groups attach to DNA segments, altering gene expression. In their study of samples from 33 patients, the research team observed a distinct DNA methylation pattern in phyllodes tumors, distinguishing them from other cancers. They also developed an algorithm that successfully reclassified samples that had initially been misdiagnosed. This advancement in understanding may lead to more accurate diagnoses and better patient outcomes.

“Disruption to epigenetic processes, such as DNA methylation patterns, is a recognized hallmark of cancer and can vary significantly between cancer types, allowing a unique cancer forensic signature,” said Professor Susan Clark, co-senior author and Head of the Cancer Epigenetics Lab at Garvan. “Harnessing the power of cutting-edge epigenetic technologies, like Digital Droplet PCR, our next step will be devising a sensitive epigenetic-based PCR test to detect phyllodes tumors that could be routinely used in pathology laboratories.”

Related Links:
Garvan Institute of Medical Research

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Homocysteine Quality Control
Liquichek Homocysteine Control

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more